The Nasdaq scored some more gains Wednesday.
News & Analysis: Amgen
Investors reacted positively to a big patent litigation win for the biotech.
An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time.
Its payouts have doubled in just five years.
Here's how these two drugmakers stack up against each other.
Should you scoop up this large-cap stock?
With the coronavirus outbreak still weighing on companies, it's time to favor those with long-term drivers of revenue growth.
The biotech giant is back on track after a strong first quarter.
Amgen's stock ripped higher in April. Here's why.
AMGN earnings call for the period ending March 31, 2020.